Anticoagulant Usage and Risk of Thromboembolic Events After Ischemic Stroke in Adults With Cancer

In this large-scale study, approximately 10% of patients with ischemic stroke had active cancer and they faced a markedly elevated short-term risk of recurrent thromboembolism and major bleeding events. Anticoagulants were infrequently prescribed after discharge and did not differentially affect the rate of ischemic or bleeding outcomes compared with alternative treatment strategies, although confounding by indication is likely. Clinical trials are required to further assess optimal antithrombotic strategies in this high-risk population.